{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:14:37Z","timestamp":1778620477365,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL15184"],"award-info":[{"award-number":["R01HL15184"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jtha.2024.05.020","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T16:33:01Z","timestamp":1716913981000},"page":"2438-2448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Concizumab improves clot formation in hemophilia A under flow"],"prefix":"10.1016","volume":"22","author":[{"given":"Megan P.","family":"Jewell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaina","family":"Ashour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine H.","family":"Baird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Manco Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth Boulden","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam R.","family":"Wufsus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Pallini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Dockal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Kjalke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith B.","family":"Neeves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.05.020_bib1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/rth2.12347","article-title":"Hemophilia without prophylaxis: assessment of joint range of motion and factor activity","volume":"4","author":"Wang","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.020_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12690","article-title":"The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: a multicenter international study","volume":"6","author":"St-Louis","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.020_bib3","series-title":"WFH guidelines for the management of hemophilia","first-page":"1","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors","volume":"26","author":"Srivastava","year":"2020"},{"key":"10.1016\/j.jtha.2024.05.020_bib4","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.05.020_bib5","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2024.05.020_bib6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.020_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe hemophilia B: a PedNet study","volume":"106","author":"Male","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.05.020_bib8","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A\u00a0bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.05.020_bib9","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A\u00a0first-in-human phase 1 study of ACE910, a novel factor VIII\u2013mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.020_bib10","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","article-title":"Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with hemophilia A with or without inhibitors","volume":"1","author":"Shima","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.05.020_bib11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.020_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/hematology.2021000253","article-title":"Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?","volume":"2021","author":"Ellsworth","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2024.05.020_bib13","doi-asserted-by":"crossref","first-page":"17838","DOI":"10.1073\/pnas.1310444110","article-title":"Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation","volume":"110","author":"Wood","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.05.020_bib14","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.020_bib15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.020_bib16","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/jth.14272","article-title":"A\u00a0randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A","volume":"16","author":"Eichler","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.020_bib17","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.020_bib18","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1182\/bloodadvances.2021006403","article-title":"Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors","volume":"6","author":"Shapiro","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.05.020_bib19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.05.020_bib20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.13260","article-title":"Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay","volume":"23","author":"Waters","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.020_bib21","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/jth.15323","article-title":"Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: in\u00a0vitro and ex\u00a0vivo analyses","volume":"19","author":"Kjalke","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.020_bib22","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0006-3495(01)76085-7","article-title":"Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition","volume":"80","author":"Kuharsky","year":"2001","journal-title":"Biophys J"},{"key":"10.1016\/j.jtha.2024.05.020_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2003-12-4352","article-title":"Platelet deposition inhibits tissue factor activity: in\u00a0vitro clots are impermeable to factor Xa","volume":"104","author":"Hathcock","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.020_bib24","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2007-08-106229","article-title":"Determination of surface tissue factor thresholds that trigger coagulation at venous and arterial shear rates: amplification of 100 fM circulating tissue factor requires flow","volume":"111","author":"Okorie","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.020_bib25","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood.V72.4.1404.1404","article-title":"Flow as a regulator of the activation of factor X by tissue factor","volume":"72","author":"Gemmell","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.020_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0026-2862(90)90031-L","article-title":"The effects of shear rate on the enzymatic activity of the tissue factor-factor VIIa complex","volume":"40","author":"Gemmell","year":"1990","journal-title":"Microvas Res"},{"key":"10.1016\/j.jtha.2024.05.020_bib27","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1021\/bi00180a034","article-title":"Transport rate limited catalysis on macroscopic surfaces: the activation of factor X in a continuous flow enzyme reactor","volume":"33","author":"Andree","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.jtha.2024.05.020_bib28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.V78.1.118.118","article-title":"Flow and the inhibition of prothrombinase by antithrombin III and heparin","volume":"78","author":"Schoen","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.020_bib29","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1161\/ATVBAHA.108.173930","article-title":"Threshold response of initiation of blood coagulation by tissue factor in patterned microfluidic capillaries is controlled by shear rate","volume":"28","author":"Shen","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.05.020_bib30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bpj.2010.12.3720","article-title":"Dilutional control of prothrombin activation at physiologically relevant shear rates","volume":"100","author":"Haynes","year":"2011","journal-title":"Biophys J"},{"key":"10.1016\/j.jtha.2024.05.020_bib31","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1074\/jbc.M111.302075","article-title":"Membrane binding events in the initiation and propagation phases of tissue factor-initiated zymogen activation under flow","volume":"287","author":"Haynes","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.05.020_bib32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.blre.2016.04.004","article-title":"Blood flow and mass transfer regulation of coagulation","volume":"30","author":"Rana","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2024.05.020_bib33","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s11538-012-9784-3","article-title":"The influence of hindered transport on the development of platelet thrombi under flow","volume":"75","author":"Leiderman","year":"2013","journal-title":"Bull Math Biol"},{"key":"10.1016\/j.jtha.2024.05.020_bib34","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2012-09-457739","article-title":"Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network","volume":"121","author":"Stalker","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.020_bib35","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s10439-013-0764-z","article-title":"Simulation of intrathrombus fluid and solute transport using in\u00a0vivo clot structures with single platelet resolution","volume":"41","author":"Voronov","year":"2013","journal-title":"Ann Biomed Eng"},{"key":"10.1016\/j.jtha.2024.05.020_bib36","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2014-01-550319","article-title":"A\u00a0systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity","volume":"124","author":"Stalker","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.020_bib37","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2014-01-550343","article-title":"A\u00a0systems approach to hemostasis: 2. Computational analysis of molecular transport in the thrombus microenvironment","volume":"124","author":"Tomaiuolo","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.020_bib38","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1182\/blood-2014-01-550335","article-title":"A\u00a0systems approach to hemostasis: 1. The interdependence of thrombus architecture and agonist movements in the gaps between platelets","volume":"124","author":"Welsh","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.020_bib39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/jth.12491","article-title":"Thrombin generation and fibrin formation under flow on biomimetic tissue factor-rich surfaces","volume":"12","author":"Onasoga-Jarvis","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.020_bib40","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/ATVBAHA.115.306537","article-title":"Platelet control of fibrin distribution and microelasticity in thrombus formation under FlowSignificance","volume":"36","author":"Swieringa","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.05.020_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078732","article-title":"The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models","volume":"8","author":"Onasoga-Jarvis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2024.05.020_bib42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/mi11010062","article-title":"Adsorption and absorption of collagen peptides to polydimethlysiloxane and its influence on platelet adhesion flow assays","volume":"11","author":"Sorrells","year":"2020","journal-title":"Micromachines (Basel)"},{"key":"10.1016\/j.jtha.2024.05.020_bib43","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1182\/blood-2010-01-260778","article-title":"Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood","volume":"115","author":"Pugh","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.020_bib44","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1538-7836.2004.00661.x","article-title":"Von Willebrand factor present in fibrillar collagen enhances platelet adhesion to collagen and collagen-induced platelet aggregation","volume":"2","author":"Bernardo","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.020_bib45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.blre.2014.12.004","article-title":"The role of cell surfaces and cellular receptors in the mode of action of recombinant factor VIIa","volume":"29","author":"Lisman","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2024.05.020_bib46","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1053\/j.seminhematol.2008.03.008","article-title":"Use of the thrombin generation test to evaluate response to treatment with recombinant activated factor VII","volume":"45","author":"Dargaud","year":"2008","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtha.2024.05.020_bib47","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/rth2.12236","article-title":"Limited factor VIIa surface localization requirement of the factor VIIa-induced overall thrombin generation in platelet-rich hemophilia A plasma","volume":"3","author":"Persson","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.020_bib48","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1172\/JCI6042","article-title":"Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin","volume":"103","author":"Kahn","year":"1999","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2024.05.020_bib49","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.bpj.2009.12.4275","article-title":"Thrombin flux and wall shear rate regulate fibrin fiber deposition state during polymerization under flow","volume":"98","author":"Neeves","year":"2010","journal-title":"Biophys J"},{"key":"10.1016\/j.jtha.2024.05.020_bib50","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1538-7836.2005.01227.x","article-title":"Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count","volume":"3","author":"Lisman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.020_bib51","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1055\/s-0038-1627453","article-title":"Suppressive role of tissue factor pathway inhibitor-\u03b1 in platelet-dependent fibrin formation under flow is restricted to low procoagulant strength","volume":"118","author":"Thomassen","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.05.020_bib52","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2141.1997.4463256.x","article-title":"Platelet activity of high-dose factor VIIa is independent of tissue factor","volume":"99","author":"Monroe","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.05.020_bib53","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/01.ATV.0000200391.70818.a9","article-title":"Glycoprotein Ibalpha-mediated platelet adhesion and aggregation to immobilized thrombin under conditions of flow","volume":"26","author":"Weeterings","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.05.020_bib54","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/hae.13259","article-title":"Recombinant factor VIIa addition to haemophilic blood perfused over collagen\/tissue factor can sufficiently bypass the factor IXa\/VIIIa defect to rescue fibrin generation","volume":"23","author":"Li","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.020_bib55","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/hae.12558","article-title":"Recombinant factor VIIa enhances platelet deposition from flowing haemophilic blood but requires the contact pathway to promote fibrin deposition","volume":"21","author":"Li","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.05.020_bib56","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood.V62.1.214.214","article-title":"Red blood cell size is important for adherence of blood platelets to artery subendothelium","volume":"62","author":"Aarts","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.05.020_bib57","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1039\/C7LC00498B","article-title":"Application of a strain rate gradient microfluidic device to von Willebrand\u2019s disease screening","volume":"17","author":"Brazilek","year":"2017","journal-title":"Lab Chip"},{"key":"10.1016\/j.jtha.2024.05.020_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054680","article-title":"Sources of variability in platelet accumulation on type 1 fibrillar collagen in microfluidic flow assays","volume":"8","author":"Neeves","year":"2013","journal-title":"PLoS One"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624003064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624003064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:27:22Z","timestamp":1778617642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624003064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1538783624003064"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.05.020","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concizumab improves clot formation in hemophilia A under flow","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}